GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (BOM:524816) » Definitions » 3-Year Revenue Growth Rate

Natco Pharma (BOM:524816) 3-Year Revenue Growth Rate : 12.60% (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma 3-Year Revenue Growth Rate?

Natco Pharma's Revenue per Share for the three months ended in Mar. 2024 was ₹59.64.

During the past 12 months, Natco Pharma's average Revenue per Share Growth Rate was 63.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 12.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 2.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Natco Pharma was 35.60% per year. The lowest was -8.60% per year. And the median was 12.30% per year.


Competitive Comparison of Natco Pharma's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Natco Pharma's 3-Year Revenue Growth Rate falls into.



Natco Pharma 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Natco Pharma  (BOM:524816) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Natco Pharma 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Natco Pharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Natco Pharma (BOM:524816) Business Description

Traded in Other Exchanges
Address
Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.

Natco Pharma (BOM:524816) Headlines

No Headlines